Prevalence of hepatitis B and hepatitis C virus infections among patients attending a sub-district government hospital in Kashipur, Uttarakhand: a hospital-based observational study

Nidhi Tiwari; Akash Chandra Mishra

doi:10.18203/2394-6040.ijcmph20264085

Authors

Nidhi Tiwari Department of Zoology, Radhey Hari Government Post Graduate College, Kashipur, Udham Singh Nagar, Uttarakhand, India Department of Zoology, Radhe Hari Government Post Graduate College, Kashipur, Udham Singh Nagar, Uttarakhand, India Department of Zoology, Radhe Hari Government Post Graduate College, Kashipur, Udham Singh Nagar, Uttarakhand, India Department of Zoology, Radhe Hari Government Post Graduate College, Kashipur, Udham Singh Nagar, Uttarakhand, India
Akash Chandra Mishra Department of Zoology, Radhey Hari Government Post Graduate College, Kashipur, Udham Singh Nagar, Uttarakhand, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20264085

Keywords:

Anti-HCV, HBsAg, Hepatitis B, Hepatitis C, JSY antenatal screening, Seroprevalence

Abstract

Background: The hepatitis B virus (HBV) and hepatitis C virus (HCV) infections frequently go unnoticed for years before developing into chronic liver disease, cirrhosis, and liver cancer. Sub-district government hospitals are frequently rural and semi-urban populations' only access to healthcare in India, but prevalence data from this tier are still hard to come by. This study was to ascertain the prevalence of HBsAg and anti-HCV in patients at a sub-district government hospital in Kashipur, as well as to look at variations over time and between the three service arms of OPD, JSY, and family planning.

Methods: This retrospective study was carried out in the laboratory records of L. D. Bhatt Sub-District Government Hospital, Kashipur from April 2025 to February 2026 comprising 6,227 HBsAg and 6,003 anti-HCV tests in OPD, JSY and Family Planning. 95% confidence intervals were used to express the prevalence; z-tests and chi-square tests of homogeneity were employed, with p<0.05 being considered significant.

Results: Total 200 of 6,003 people had anti-HCV (3.33%, 95% CI 2.88–3.79%) and 98 of 6,227 people had reactive HBsAg (1.57%, 95% CI 1.26-1.88%). HCV positivity was significantly higher (z=6.30, p<0.001). Monthly positivity varied significantly from month to month (HBsAg χ2=21.42, p=0.018; HCV χ2=22.89, p=0.011), with a December 2025 spike in HBsAg and a November 2025 spike in HCV driving the range of 0.81% to 3.53% for HBsAg and 1.63% to 5.88% for HCV.

Conclusions: Both infections are still prevalent enough to warrant ongoing screening, with HCV being noticeably more prevalent than HBV. Prenatal HBsAg screening should be universal rather than selective, as evidenced by the high percentage of cases discovered through JSY.

References

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38.

World Health Organization. Global Hepatitis Report 2024, 2024. Available at: https://www.who.int/hepatitis. Accessed 15 May 2026.

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.

Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Systematic review and meta-analysis of prevalence of hepatitis B in India. Ind Pediatri. 2007;44(9):663-74.

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatol. 2015;61(1):77-87.

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatol. 2009;49(4):1335-74.

Indian Council of Medical Research (ICMR). National Guidelines for Viral Hepatitis Management, 2020. Available at: https://nvhcp.mohfw.gov.in/common_libs/diagnosis-management-viral-hepatitis.pdf. Accessed 15 May 2026.

Ministry of Health and Family Welfare (MoHFW), Government of India. National Viral Hepatitis Control Programme: Operational Guidelines, 2018. Available at: https://nvhcp.mohfw.gov.in/common_libs/Operational_Guidelines.pdf. Accessed 15 May 2026.

Gupta E, Bajpai M, Choudhary A. Prevalence of hepatitis B and C infections in hospital-based populations. Ind J Publ Heal. 2016;60(2):154-8.

Sharma S, Sharma R, Singh G. Prevalence of hepatitis B and C infections among patients attending tertiary care hospitals. J Clin Diagnos Res. 2018;12(6):LC01-4.

Mukhopadhyay AK, Chakrabarti S. Hospital-based prevalence of hepatitis B and C infections. Ind J Med Microbiol. 2015;33(2):215-20.

Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Nat Med J India. 2006;19(4):203-17.

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody prevalence. Hepatol. 2013;57(4):1333-42.

Kumar R, Gupta S, Kaur A. Hospital-based screening of hepatitis B and hepatitis C infections among patients attending tertiary healthcare facilities. Int J Comm Medi Pub Heal. 2020;7(6):2214-9.

Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Revi. 2006;28:112-25.

Puri P. Tackling the hepatitis B disease burden in India. J Clin Experiment Hepatol. 2014;4(4):312-9.

Singh MP, Ratho RK. Seroprevalence of hepatitis B and C virus infections in hospital settings. J Laborat Phys. 2017;9(1):15-9.

Chandra M, Khaja MN, Farees N, Poduri CD, Hussain MM, Aejaz Habeeb M, et al. Prevalence, risk factors and genotype distribution of HCV and HBV infection in India. J Publ Heal. 2009;17(5):345-52.